- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07642440
Suprapubic Drainage During Transurethral Cystolithotripsy for Large Bladder Stones (SPT-CYSTO Tria)
Transurethral Cystolithotripsy With Versus Without Adjunctive Suprapubic Tube Drainage for Bladder Stones >2 cm: A Prospective Randomized Controlled Trial
Bladder stones larger than 2 cm are commonly treated by endoscopic fragmentation through the urethra. During transurethral cystolithotripsy for large stones, the procedure may be prolonged because of poor visibility, stone dust, bladder overdistension, and repeated need for irrigation or evacuation.
This randomized controlled trial will compare standal Holmium:YAG laser cystolithotripsy using a 17 Fr cystoscope sheath with the same procedure plus an adjunctive 8 Fr suprapubic catheter used only for bladder drainage during the operation. The suprapubic catheter will not be used for stone fragmentation or stone extraction.
The main outcome will be total operative time. Secondary outcomes will include fragmentation and clearance time, laser activation time, total laser energy, irrigation volume, visibility-related interruptions, stone-free rate at 30 days, complications, catheter duration, postoperative pain, and hospital stay.
Visão geral do estudo
Status
Condições
Descrição detalhada
This is a prospective, randomized, controlled, parallel-group clinical trial conducted at the Department of Urology, Beni-Suef University Hospital, Faculty of Medicine, Beni-Suef University, Egypt. Adult patients with radiologically confirmed bladder stones greater than 2 cm who are scheduled for elective transurethral cystolithotripsy will be enrolled after written informed consent.
Participants will be randomized in a 1:1 ratio into two groups. The control group will undergo standardized transurethral Holmium:YAG laser cystolithotripsy using a 17 Fr cystoscope sheath with conventional irrigation and transurethral evacuation only. The experimental group will undergo the same procedure with adjunctive 8 Fr suprapubic catheter drainage inserted under ultrasound guidance and cystoscopic visualization. The suprapubic catheter will be connected to free drainage during lithotripsy to assist bladder decompression and irrigation outflow. It will not be used for stone fragmentation, stone extraction, tract dilation, sheath placement, or percutaneous cystolithotripsy.
All procedures will use the same standardized cystoscopic access, Holmium:YAG laser platform, irrigation system, and transurethral evacuation method. The primary outcome is total operative time, measured from cystoscope insertion into the urethra until endoscopic confirmation of complete stone clearance and completion of final urethral catheter placement. Postoperative follow-up will continue for 30 days, including assessment of stone-free status by imaging and recording of perioperative complications.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Hany F Badawy, MD
- Número de telefone: +201149525028
- E-mail: HANYFATHY86@GMAIL.COM
Locais de estudo
-
-
Beni Suweif Governorate
-
Banī Suwayf, Beni Suweif Governorate, Egito
- Recrutamento
- Department of Urology- Beni-Suef University Hospitals
-
Investigador principal:
- Hany F Badawy, MD
-
Contato:
- Hany F Badawy, MD
- Número de telefone: 01149525028
- E-mail: HANYFATHY86@GMAIL.COM
-
Contato:
- E-mail: HANYFATHY86@GMAIL.COM
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Age 18 years or older.
- Radiologically confirmed bladder stone with maximum diameter greater than 2 cm.
- Scheduled for elective transurethral cystolithotripsy.
- Sterile urine culture before surgery, or adequately treated urinary tract infection according to culture sensitivity.
- Fit for spinal or general anesthesia.
- Ability to provide written informed consent.
Exclusion Criteria:
- Urethral stricture preventing safe cystoscopic access.
- Active uncontrolled urinary tract infection or sepsis.
- Neurogenic bladder with severely impaired bladder emptying requiring chronic catheterization.
- History of bladder cancer or suspected bladder tumor requiring simultaneous transurethral resection of bladder tumor.
- Coagulopathy or uncorrected bleeding tendency.
- Patients requiring concomitant transurethral resection of the prostate, Holmium laser enucleation of the prostate, or other prostate surgery in the same session.
- Previous pelvic radiotherapy or major lower urinary tract reconstruction.
- Pregnancy.
- Refusal to participate.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Standard Transurethral Cystolithotripsy
Participants assigned to this arm will undergo standardized transurethral Holmium:YAG laser cystolithotripsy using a 17 Fr cystoscope sheath with conventional irrigation and transurethral evacuation only, without adjunctive suprapubic catheter drainage.
|
Standardized transurethral Holmium:YAG laser cystolithotripsy performed through a 17 Fr cystoscope sheath, with conventional irrigation and transurethral evacuation of stone dust and fragments.
A urethral Foley catheter will be inserted at the end of the procedure.
This procedure will be performed in both study arms.
|
|
Experimental: Transurethral Cystolithotripsy With Suprapubic Drainage
Participants assigned to this arm will undergo the same standardized transurethral Holmium:YAG laser cystolithotripsy using a 17 Fr cystoscope sheath, with adjunctive 8 Fr suprapubic catheter drainage inserted under ultrasound guidance and cystoscopic visualization for bladder drainage and decompression during lithotripsy.
No stone fragmentation or extraction will be performed through the suprapubic route
|
Insertion of an 8 Fr suprapubic catheter under ultrasound guidance and cystoscopic visualization during transurethral cystolithotripsy.
The catheter will be connected to free drainage to assist bladder decompression and irrigation outflow during lithotripsy.
It will not be used for stone fragmentation, stone extraction, tract dilation, sheath placement, or percutaneous cystolithotripsy.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Total Operative Time
Prazo: During the surgical procedure
|
Total operative time will be measured in minutes from insertion of the cystoscope into the urethra until endoscopic confirmation of complete bladder stone clearance and completion of final urethral catheter placement.
In the suprapubic drainage group, the time required for insertion of the 8 Fr suprapubic catheter will be included because the study evaluates the overall procedural efficiency of adding adjunctive suprapubic cathe+ drainage
|
During the surgical procedure
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Stone Fragmentation and Clearance Time
Prazo: During the surgical procedure
|
Time measured in minutes from the start of Holmium:YAG laser lithotripsy until endoscopic confirmation of complete bladder stone fragmentation and clearance
|
During the surgical procedure
|
|
Total Laser Energy
Prazo: During the surgical procedure
|
Total Holmium:YAG laser energy delivered during cystolithotripsy, recorded in joules from the laser device.
|
During the surgical procedure
|
|
Visibility-Related Interruptions
Prazo: During the surgical procedure
|
Number of intraoperative interruptions of lithotripsy due to poor endoscopic vision, stone dust, bladder overdistension, clot, or need for evacuation or irrigation adjustment.
|
During the surgical procedure
|
|
Urethral Catheter Duration
Prazo: From end of surgery until catheter removal, up to 30 days
|
Duration of postoperative urethral Foley catheterization, measured from the end of surgery until catheter removal.
|
From end of surgery until catheter removal, up to 30 days
|
|
Postoperative Pain Score
Prazo: 6 hours and 24 hours after surgery
|
Postoperative pain will be assessed using the Visual Analogue Scale.
The scale ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain.
Higher scores indicate worse pain.
|
6 hours and 24 hours after surgery
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Hany F Badawy, MD, Faculty of Medicine, Beni-Suef University hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Urogenitais Masculinas
- Cálculos
- Condições Patológicas, Anatômicas
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Urolitíase
- Cálculos urinários
- Doenças da Bexiga Urinária
- Condições Patológicas, Sinais e Sintomas
- Cálculos na Bexiga Urinária
Outros números de identificação do estudo
- FMBSUREC-07062026a-Badawy
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .